Antje Blank

Treatment of chronic hepatitis D with the entry inhibitor myrcludex B: First results of a phase Ib/IIa study

Pavel Bogomolov, A. A. Alexandrov, M. V. Macievich et al. · Journal of Hepatology · 2016 · 390 citations

Pharmacy, Internal Medicine, Pharmacotherapy +11

First-in-human application of the novel hepatitis B and hepatitis D virus entry inhibitor myrcludex B

Antje Blank, Christoph Markert, Nicolas Hohmann et al. · Journal of Hepatology · 2016 · 218 citations

Pharmacy, Medicinal Chemistry, Pharmacology +9

A Phase 3, Randomized Trial of Bulevirtide in Chronic Hepatitis D

Heiner Wedemeyer, Soo Aleman, Maurizia Rossana Brunetto et al. · New England Journal of Medicine · 2023 · 215 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacotherapy +13

A functional GTP-binding motif is necessary for antiviral activity of Mx proteins

Fernando J. Pitossi, Antje Blank, Anja Schröder et al. · Journal of Virology · 1993 · 182 citations · Full text

Life Sciences, Biology, Molecular Biology +15

Safety and efficacy of bulevirtide in combination with tenofovir disoproxil fumarate in patients with hepatitis B virus and hepatitis D virus coinfection (MYR202): a multicentre, randomised, parallel-group, open-label, phase 2 trial

Heiner Wedemeyer, Katrin Schöneweis, Pavel Bogomolov et al. · The Lancet Infectious Diseases · 2022 · 158 citations

Pharmacy, Pharmacology, Pharmacotherapy +13